Episodes

  • Corporate Cash and Elections: Unpacking the Influence
    Nov 16 2026

    Recorded two weeks before the US midterms, we examine what corporate campaign contributions do, their risks, and the behavioral biases behind them, arguing individual donations are usually too small to matter while corporate giving is central. Using Apple, Microsoft, Pfizer, and JPMorgan as case studies across the US, Ireland, Germany, and China, we conclude large firms’ donations are generally not ideological but driven by business self-interest, status quo bias, and uncertainty aversion, often hedging by supporting both parties and incumbents likely to hold power or sit on influential committees. We examine donations as buying access and ensuring a company’s views are heard rather than guarantees of policy change, while noting other influence channels abroad (investment, associations, committees, direct and indirect lobbying). Apple is highlighted as not donating to candidates, likely due to strong federal contract leverage, and JPMorgan’s ownership of Chinese financial firms is discussed as a route to market access and indirect political influence.

    Show More Show Less
    33 mins
  • Revolutionizing Learning: The AI Transformation in Academia
    Oct 26 2026

    In this episode of Behavior and Risk, we explore how rapidly expanding AI spending and adoption are reshaping academia, creating both opportunities for customized learning and course development and risks of student shortcuts that undermine critical thinking. We compare today’s debates to early internet-era fears, arguing AI is a permanent paradigm shift and education must adapt by teaching students how to use AI responsibly and effectively for work. We discuss Columbia University’s shift toward allowing AI use due to detection challenges and workplace relevance, and emphasize “authentic assessments,” higher-level application questions, prompt grading, and quality control through fact-checking. Examples include redesigning medical assignments to build a Parkinson’s community program, using oral “hot seat” Socratic evaluation, AI-assisted grading with rubrics, and workplace training on tools like Copilot where success depends on asking the right questions and validating outputs.

    Show More Show Less
    44 mins
  • Shareholder vs. Stakeholder Organizations: Agency, Incentives, and Risk Decision-Making
    Oct 5 2026

    In this episode, we compare shareholder-oriented and stakeholder-oriented organizations, defining shareholder primacy as maximizing profits, share price, and dividends (e.g., GE under Jack Welch, ExxonMobil) and contrasting it with stakeholder models that balance employees, customers, communities, and the environment for long-term value (e.g., Unilever under Paul Polman, Patagonia), shaped by differing legal and cultural frameworks such as Delaware corporate law, Germany’s co-determination, and EU sustainability directives. We argue the “stakeholder good, shareholder bad” framing is oversimplified, explore how agency problems between owners and management affect decisions, and note stakeholder can mean many different constituencies. The discussion highlights time-horizon bias and short-term earnings pressure in shareholder models, impacts on R&D and innovation, and how activist investors and private equity influence governance, risk custody, and the need for clear risk messaging and metrics.

    Show More Show Less
    36 mins
  • The Iron Law of Midterms: Behavioral Forces Shaping House Flips
    Sep 7 2026

    The episode examines the “iron law of midterms.” Since World War II the party holding the White House has lost ground in Congress in 18 of 20 midterm elections. We discuss early 2026 signals such as presidential approval in the high thirties, cool independent voters, and models suggesting a potential House shift. We explore behavioral explanations beyond topline numbers, focusing on turnout changes between presidential and midterm electorates, salience and recency effects, retrospective voting in the US, and how loss aversion can overwhelm uncertainty aversion to drive anti-incumbent swings. We contrast US two-party choice complexity with Europe’s more prospective voting, discuss perceived equivalence between president and party, and consider why presidential incumbency can remain strong even as House seats flip. We also debate conflicting forecasts, predictive markets, polling errors, gerrymandering, and shifting party coalitions as factors that could alter the usual pattern in 2026.

    Show More Show Less
    40 mins
  • Why Charities Are Uniquely Vulnerable: Identity, Incentives, and Risk in the 501(c)(3) World
    Aug 21 2026

    In this episode, we explore why nonprofits and charities, while generally beneficial, are uniquely susceptible to malfeasance due to a regulatory hodgepodge, donor identity attachment, and management incentives. We explore how donations often involve reciprocity in the form of internal rewards (wellbeing, moral elevation, guilt reduction) tied to self-concept, which can be exploited and can sustain giving even after documented scandals (e.g., United Way). We contrast rogue individuals in otherwise good organizations with inherently fraudulent charities and note how ethics can gradually slip. Key risk domains include inconsistent 501(c)(3) oversight with audit-avoidance thresholds, fundraising and donor concentration risks, seasonal revenue forecasting risk,reliance on “vibes” and branding, operational risks (fraud, data breaches, litigation, compliance), volatile volunteer dependence, reputational fragility, and “boiled frog” cultures of small lapses escalating. We conclude: avoid over-identifying with charities, don’t run them like for-profits, and don’t do due diligence by vibes.

    Show More Show Less
    44 mins
  • The Price of Pain: How the Opioid Epidemic Was Engineered
    Jul 20 2026

    The episode argues that the opioid crisis was not a failed risk calculation but a knowingly scaled, dangerous product driven by “profit first” incentives, echoing a broader cultural shift. It focuses on Purdue Pharma and the Sackler family, who had internal data undermining claims that OxyContin was less addictive yet aggressively marketed it, influenced guidelines, and shaped regulators. We explore how authority bias, framing, social proof, and status quo effects were leveraged through pain societies, “pain as the fifth vital sign,” influential physicians, and normalized side-effect disclaimers to manipulate perceived risk. We discuss conflicts of interest and regulatory capture at the FDA, plus distributors ignoring data red flags despite duties to monitor suspicious orders. Concluding, we call for risk programs that account for financial motivation but extend beyond profit to long-term human well-being.

    Show More Show Less
    48 mins
  • The Rise and Fall of Archegos: Unveiling Information Asymmetry in Financial Markets
    Jul 6 2026

    This episode reviews the rise and fall of Archegos, the 2013 Midtown Manhattan family office run by Bill Hwang, who previously settled SEC insider-trading charges at Tiger Asia. Using financing from six banks—Goldman Sachs, Morgan Stanley, Credit Suisse, Nomura, Deutsche Bank, and UBS—Archegos employed heavy leverage and total return swaps to build concentrated, largely undisclosed exposures, amplifying gains as stocks rose. In March 2021, declines— especially around ViacomCBS—triggered margin calls, forced selling, and a downward spiral that led to a bank fire sale, roughly $20B in Archegos losses and about $10B in combined bank losses, with Credit Suisse and Nomura hit hardest. The discussion highlights Hwang’s information-control style, misrepresentation to banks, behavioral dynamics like overconfidence and risk perception, a prisoner’s-dilemma unwind among banks, and the central lesson: reduce information asymmetry through due diligence in complex, high-stakes transactions.

    Show More Show Less
    1 hr and 9 mins
  • Decoding AI in Healthcare: Regulation, Risk, and Reality
    Jun 15 2026

    This episode of Behavior and Risk examines how AI is being deployed across healthcare—from chatbots and personalized treatment planning to imaging and surgical tools—and focuses on the regulatory landscape, especially in the United States. We argue U.S. oversight is a patchwork that relies heavily on the FDA’s “substantial equivalence” pathway (97% of authorizations), a framework rooted in older standards, while AI systems function as black boxes and evolve rapidly. We discuss information asymmetry between developers and regulators, FDA staffing losses, and how incentives and cognitive biases (inertia, conflict aversion, availability, groupthink, intertemporal discounting) may lead to underappreciated risk. We cite concerns about patient inability to opt out or even be informed and highlight Epic’s sepsis prediction model’s performance issues and potential harm. The conversation ends by emphasizing the need to reduce uncertainty and communicate AI risks clearly without causing cognitive overload.

    Show More Show Less
    46 mins